Sabby Management’s Acceleron Pharma XLRN Stock Holding History

Sabby Management’s Portfolio XLRN Stock Details XLRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-8,646	Closed	-$338K	–	197
2018 Q1	$338K	Buy	+8,646	New	+$368K	0.04%	109
2016 Q2	–	Sell	-50,000	Closed	-$1.32M	–	352
2016 Q1	$1.32M	Buy	+50,000	New	+$1.45M	0.07%	135

Other funds holding XLRN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Sabby Management's XLRN Position: Q2 2018 in Review

Sabby Management sold out of Acceleron Pharma (XLRN) in Q2 2018, closing a stake of 8,646 shares — an estimated $338K sold.

Sabby Management first reported a position in XLRN in Q1 2016 and held it in 2 quarters. The position peaked at $1.32M in Q1 2016. 170 funds tracked by Wall St. Rank hold XLRN as of Q2 2018.

Sabby Management reported no remaining Acceleron Pharma position as of Q2 2018 after selling out during the quarter.
Sabby Management sold 8,646 Acceleron Pharma shares in Q2 2018, an estimated $338K.
Sabby Management first reported a position in Acceleron Pharma in Q1 2016 and held it in 2 quarters.
Sabby Management's Acceleron Pharma position peaked at $1.32M in Q1 2016.
170 funds tracked by Wall St. Rank held Acceleron Pharma as of Q2 2018.

Based on Sabby Management's 13F filing for Q2 2018, filed 14 Aug 2018.